Blood biomarker changes following therapeutic hypothermia in ischemic stroke
Palà, Elena (Vall d'Hebron Institut de Recerca (VHIR))
Penalba, Anna (Vall d'Hebron Institut de Recerca (VHIR))
Bustamante, Alejandro (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
García-Berrocoso, Teresa (Vall d'Hebron Institut de Recerca (VHIR))
Lamana-Vallverdu, Marcel (Vall d'Hebron Institut de Recerca (VHIR))
Meisel, Christian (Labor Berlin-Charité Vivantes)
Meisel, Andreas (Charité-Universitätsmedizin Berlin)
van der Worp, H. Bart (University Medical Center Utrecht)
R Macleod, Malcolm (University of Edinburgh)
Kallmünzer, Bernd (Universitätsklinikum Erlangen)
Schwab, Stefan (Universitätsklinikum Erlangen)
Montaner, Joan (Vall d'Hebron Institut de Recerca (VHIR))

Data:	2023
Resum:	Therapeutic hypothermia is a promising candidate for stroke treatment although its efficacy has not yet been demonstrated in patients. Changes in blood molecules could act as surrogate markers to evaluate the efficacy and safety of therapeutic cooling. Blood samples from 54 patients included in the EuroHYP-1 study (27 treated with hypothermia, and 27 controls) were obtained at baseline, 24 ± 2 h, and 72 ± 4 h. The levels of a panel of 27 biomarkers, including matrix metalloproteinases and cardiac and inflammatory markers, were measured. Metalloproteinase-3 (MMP-3), fatty-acid-binding protein (FABP), and interleukin-8 (IL-8) increased over time in relation to the hypothermia treatment. Statistically significant correlations between the minimum temperature achieved by each patient in the hypothermia group and the MMP-3 level measured at 72 h, FABP level measured at 24 h, and IL-8 levels measured at 24 and 72 h were found. No differential biomarker levels were observed in patients with poor or favorable outcomes according to modified Rankin Scale scores. Although the exact roles of MMP3, FABP, and IL-8 in hypothermia-treated stroke patients are not known, further exploration is needed to confirm their roles in brain ischemia. Changes in blood molecules could act as surrogate markers to evaluate the efficacy and safety of therapeutic cooling. After evaluating a panel of 27 biomarkers including matrix metalloproteinases, cardiac, and inflammatory markers in the blood of patients treated with hypothermia and controls, MMP-3, FABP, and IL-8 increased over time in relation to the hypothermia treatment. These proteins deserve further exploration to confirm their role in brain ischemia.
Ajuts:	Instituto de Salud Carlos III PI18/00804 European Commission 278709
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Biomarkers ; Hypothermia ; Ischemia ; Stroke
Publicat a:	Brain and behavior, Vol. 13 (september 2023) , ISSN 2162-3279

DOI: 10.1002/brb3.3230
PMID: 37721534

7 p, 648.3 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats